A dual-column retention index method is described for quantitative gas chromatographic (GC) screening of 26 benzodiazepine drugs and metabolites in the blood using DB-5 and DB-17 capillary columns and electron capture detection. The method involves a one-step, smaU-scale liquid-liquid extraction with ethyl acetate and derivatization with N-methyI-N-(tert-bulyldimethylsilyl)trifluoroacetamide with 1% tert-butyldimethylsilyl chloride. The results from the GC screening of 514 postmortem blood samples were compared to those obtained from urine immunoassay (Syva ETSplus with a 200-ng/mL cutoff). Both methods gave a negative result in 284 cases and a positive result in 149 cases. In 48 cases, urine was negative by immunoassay but blood was positive by GC. The opposite situation (blood negative, urine positive) was detected only in four cases. In 29 cases, an invalid result was obtained by urine by immunoassay: 26 blood samples of those cases were negative and three samples positive by GC. In postmortem forensic toxicology, the present GC method seems to be a good alternative to the common combination of urinary immunoassay followed by quantitative analysis of blood by chromatography.
Introduction
In urinary drug testing, the presence of benzodiazepines is usually revealed by screening urine samples by immunochemical techniques and confirming positive findings by chromatographic methods. In postmortem toxicology and in drugs and driving investigations, it is also necessary to perform a quantitative benzodiazepine determination of the blood in order to estimate the degree of toxicity. Although several methods, especially gas chromatography-mass spectrometry (GC-MS), have been published to detect benzodiazepines in urine (I-15), there are fewer methods for a broad range quantitative screening analysis in the whole blood. These methods ' Presented in pan at the SOFT-TIAFT meeting, AJl~Jquerque, New Mexico, October 1998. mainly involve gas chromatography (GC) (16) (17) (18) (19) (20) or liquid chromatography (HPLC) (21) (22) (23) (24) . By using GC methods, benzodiazepines are usually analyzed separately from other drugs because of their distinctive chromatographic properties. Benzodiazepines are fairly polar compounds with low volatility and low blood concentrations, and an electron withdrawing group makes them especially amenable to electron capture (EC) detection. Because of their polarity, many benzodiazepines and particularly their metabolites are difficult to analyze at low levels without derivatization of the active hydroxyl or amide groups.
The present paper describes a quantitative dual-column GC retention index (RI) method for screening benzodiazepines in the blood and compares the performance of the GC blood analysis with a urine immunoassay in 514 successive postmortem cases.
was a donation from the Republican Centre of Forensic Medicine (Moscow, Russia). The R-series RI standards ( Figure  1 ) were synthesized in the authors' laboratory (25) . The compounds R2, R6, R8, R12, R14, and R16 were used as qualitative standards for calculating the retention index values of unknown peaks. R2, structurally closest to the benzodiazepine drugs, was also used as a quantitative internal standard. The stock standard solutions were prepared by weighing each of the pure substances into a 4-rnL vial and adding methanol (acetonitrile for norclobazarn) in order to obtain a concentration of 1 mg/mL. The stock solutions were further diluted with methanol (norclobazam solution with acetonitrile) to obtain working solutions of 100, 10, and 1 IJg/mL.
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Sample preparation for GC and GC-MS
The centrifuge tubes were silanized before use by dipping them into a 0.2% solution of Aquasil in water, rinsing with water, and allowing to dry at room temperature for 24 h. The working blood standards were prepared by adding the standard solutions into centrifuge tubes (three or four compounds per one tube) and evaporating the solvent to dryness under a gentle stream of nitrogen.
Whole blood (bovine blood for working blood standards) (1 g) was transferred into a centrifuge tube (10-ram i.d.). The internal standard 1,3-dihydro-l-ethyi-7-fluoro-5-(4-fluorophenyl)-2H-1,4-benzodiazepin-2-one (R2) (0.3 Ilg) in methanol (50 I~L) and saturated ammonium chloride solution (0.5 mL) were added to obtain a pH of 7.4, and the mixture was shaken. The sample was extracted with ethyl acetate (0.5 mL) in a vortex mixer for 5 rain and centrifuged. An aliquot of the organic phase (100 ~tL) was transferred to an autosampler vial (07-CPV(A), Chromacol, Trumbull, CT) and evaporated to dryness in order to eliminate the traces of water in ethyl acetate that disturb the silylation procedure. The residue was reconstituted with 100 IJL of ethyl acetate, and 50 IlL of MTBSTFA with 196 TBDMSCI was added. The vial was capped with a crimp cap (8-AC5, Chromacol) and heated at 85~ for 30 rain.
Urine samples were hydrolyzed by adding 10 pL of [3-glucuronidase to 1 mL of urine and heating for 40 min at 40~ The rest of the sample preparation procedure was identical to the procedure for blood samples.
GC
The GC was a Micromat HRGC 412 (HNU-Nordion, Helsinki, Finland) with two EC detectors. The fused silica capillary columns were DB-5 (15 m x 0.32-mm i.d., 0.1-~tm film thickness) and DB-17 (15 m x 0.32-ram i.d., 0.15-1am film thickness, J&W Scientific, Folsom, CA). The columns entered a single injector through a two-hole ferrule. The Grob-type split/splitless injector was operated in the splitless mode. Silanized glass wool was used inside the liner. Automated injections were performed with a CTC A200S autosampler (CTC Analytics, Zwingen, Switzerland) using a 1.5-pL apparent injection volume. The autosampler was set to take the RI standards in ethyl acetate from a separate vial prior to the sample injection.
The carrier gas was helium with a flow rate of approximately 3.0 mL/min for DB-5 and 2.0 mUmin for DB-17 (130~ The split flow rate was 15 mL/min, and the septum purge flow rate 3 mL/min. The detector makeup gas (5% CH4 in At) flow rate was 25 mL/min. The injector and detector temperatures were 250~ and 300~ respectively. The splitless time was 0.6 rain. The oven temperature was initially held at 130~ for 0.6 rain, increased by 25~ to 220~ and then increased by 5~ to 290~ which was held for 2 rain.
GC-MS
GC--MS was performed with a Hewlett-Packard (Wilmington, DE) 5972 mass selective detector coupled to a HP 5890 series I1 GC equipped with a HP-1 (12 m x 0.20-ram i.d., 0.33-pro film thickness) capillary column. The GC-MS was operated by Chemstation software and the GC was used in the splitless mode. The injector port temperature was 250~ and the transfer line temperature was 280~ The oven temperature was initially held at 130~ for 0.5 rain and then increased by 15~ to 300~ which was held for 2 min.
Data processing in GC
Data processing was performed with MS Windows-based SCWorkStation 3.0 software (Sunicom, Helsinki, Finland). The program was set to automatically identify the internal RI standards by pattern recognition, to calculate the temperature programmed (linear polygonal) RI values of all detected peaks, and to compare them with library data (substance windows). A part of the SC-Workstation, the SC-Compare 1.11 software, first identifies all substances in the library that could match a peak, separately on each column. It then compares the data Journal of Analytical Toxicology, Vol. 24, January/February 2000 from the single columns and reports only those substances that were identified with both columns in an easily interpretable form (26) .
Urine immunoassay
Urine samples were centrifuged and the supernatants were analyzed by Emit | d.a.u. TM (ETSplus) benzodiazepine assay (Syva, San Jose, CA) using a 200-ng/mL cutoff value.
Postmortem specimens
For the blood-urine comparison study, 514 successive postmortem cases in which both peripheral blood and urine was sent for toxicological analysis by the medical examiners were used.
Results
The GC RI values of 26 benzodiazepine drugs and metabolites and the linearity of quantitation, limit of detection, and limit of quantitation in the blood are presented in Table I . The linearity was good on both columns, the r 2 exceeding 0.99, except for chlordiazepoxide, which decomposed producing several peaks. All the compounds could be detected at the therapeutic level and most of them at the low therapeutic level. A concentration in the blood that resulted in a signal three times the baseline noise was used as the criterion for the limit of detection. The EURACHEM approach with 10% precision was used for the calculation of the limit of quantitation. In the EURACHEM approach, samples of decreasing amounts of the analyte are injected six times. The calculated relative standard deviation is plotted against the analyte amount, and the amount that corresponds to the previously defined required precision is equal to the limit of quantitation (27) .
The extraction recovery was over 80% for each compound. The recoveries were determined by comparing values obtained with unextracted and extracted standards. An unextracted standard was used as a 100% recovery reference. Three blood samples containing the middle concentration of working blood standards for each compound (Table I) were extracted normally except that the internal standard was added after extraction before derivatization. The results of the three experiments were then averaged. The long-term quantitative (concentrations) and qualitative (retention indices) precision of selected compounds was good on both columns (Tables II and III) . Figure 2 shows the separation of all compounds studied (except chlordiazepoxide) together with the co-injected R! standards on DB-5 and DB-17 columns. Figures 3 and 4 show the dual-column chromatogram from an actual autopsy blood sample and the SC-Compare analysis report for the case, respectively. A selection of compounds that could be detected by ECD was tested for interference (Table IV) . Although some of the compounds might be confused with benzodiazepines in a single column, none of them interfered with benzodiazepines in the present dual-column procedure.
The results from the comparison study between the GC blood analysis and urine immunoassay are summarized in Table V 
Discussion
The dual-column technique using DB-5 and DB-170I columns has been proven to improve the reliability of the identification of unknown substances in GC drug screenin~l compared to a single-column technique (26) . In the present study, the DB-17 column was used instead of DB-1701 be. cause the day-to-day precision of RIs on DB-1701 was poor. This is interesting because in our earlier studies with under" ivatized benzodiazepines the precision of RIs on a similar sta" tionary phase was very good (25) . Depending on the compound, the RI values increased or decreased drastically during the 12-week period on DB-1701, unlike on DB-17, where the variation of RI values was smaller and more randor0. Also the detection limits of some compounds, especially 7" aminoclonazepam-TBDMS, got higher during the 12-week pe. riod on DB-1701. Possibly, the excess of the silylation reagenl in the injection solvent reacted with the cyanopropyl groups of DB-1701 and changed the chemical composition of the sta' tionary phase. Although a few benzodiazepine compounds co-elute on one column (Figure 2) , there is no pair of compounds that coelute on both columns. In practice, the only possible combination of benzodiazepines that may cause identification problems is the simultaneous presence of midazolam, oxazepam and nitrazepam. Oxazepam-TBDMS and nitrazepam-TBDMS co-elute on DB-5 and nitrazepam-TBDMS and midazolam nearly co-elute on DB:17. Small amounts of nitrazepam may thus be missed. Of nonbenzodiazepine drugs, lamotrigine and some barbiturates, especially cyclobarbital, brallobarbital, and phenobarbital, produce big fronting peaks or a group of peaks and may thus disturb the integration of peaks eluting before them (Table IV) .
A disadvantage of the method is the fact that the amino (Table II) are based on four determinations during a four-week period using a threepoint calibration and without recalibration during that time.
To maintain the performance of the method, quantitative and qualitative calibration should be done at least once a month and the injector liner should be changed once a week. In addition, a few centimeters at the beginning of the column may be cut, if necessary, to maintain a good peak shape of triazoloor irnidazobenzodiazepines. One pair of columns can be used for the analysis of approximately 1400 blood extracts (four months of daily use in our laboratory).
Although a few GC methods for screening benzodiazepines in blood have been published earlier, the dual-column approach with two different stationary phases has only been used once (19) , and two similar columns with two different detectors (electron capture, nitrogen selective) were used twice (18, 20) . The quantitative precision of these methods has been generally well documented, and interfering compounds were tested in three papers (18) (19) (20) , but the qualitative precision, implying the reliability of identification, is hardly discussed at all. The identification of compounds in two published methods was based on the relative retention time (19, 20) and on the sole absolute retention time in three methods (16) (17) (18) , but none of the methods used retention indices as the identification parameter. Although derivatization is widely used in GC-MS to improve the chromatographic properties of benzodiazepines, it has not been used in GC screening procedures in the blood. However, there is a target analysis for alprazolarn and rnetabolites after acylation (29) .
In the blood-urine comparison study, some of the bloodpositive and urine-negative results (Table VI) can be explained by a recently given dose during resuscitation. In most cases, however, the differences are due to different concentrations in the respective specimens and the performance of the analysis technique. It has been reported that enzymatic hydrolysis of glucuronide conjugates is required to ensure adequately sensitive detection of oxazeparn by EMIT d.a.u. (30) and oxazeparn, (31, 32) . In Table VI the blood benzodiazepine concentrations are, in all cases, at the therapeutic or subtherapeutic level and obviously have no contribution to the death. However, in crime-related cases, all drug findings may be significant. The four positive urine results in Table VII can be explained by the longer presence of the glucuronide conjugates in the urine than the parent drug in the blood. The results suggest that in postmortem forensic toxicology, benzodiazepines are more reliably detected in the blood by advanced GC methods than in urine by irnmunoassay. Furthermore, the GC method used allows simultaneous quantitation of the drugs. The blood drug concentrations are fairly low in many cases, and consequently, derivatization is required for high sensitivity. The results also reveal the widespread usage of benzodiazepines: 39.7% of the postmortem cases received for drug screening were positive for benzodiazepines.
